IRIS | Institutional Research Information System

Publication

Now showing 1 - 10 of 58
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Open Access ,
    Structural basis of IgLON5 autoantibody recognition in autoimmune encephalitis
    (2026-09-11)
    Roux, Angelique
    ;
    Schelling, Rachel
    ;
    Vinyals-Sales, David
    ;
    Sabater, Lidia
    ;
    Winiger, Rahel R.
    Anti-IgLON5 disease is a rare neuro-immunological disorder characterized by autoantibodies targeting the neuronal adhesion molecule IgLON5, as well as profound brain dysfunction and tau pathology. Despite its severe clinical manifestations, the molecular basis of antibody recognition and its contribution to disease pathogenesis is poorly understood. Here, we characterize the B cell receptor repertoire of a patient with anti-IgLON5 disease, revealing marked diversity and no evidence of dominant clonal expansion. We isolate a human monoclonal IgG4 antibody that binds IgLON5 with high affinity and determine the structure of its Fab in complex with IgLON5 using cryo-electron microscopy. Biochemical and structural analyses show that antibody binding preserves IgLON5 adhesive interfaces while remaining compatible with clustering of IgLON5 on the cell surface. Analysis of the germline-reverted precursor suggests that IgLON5 recognition is already present before affinity maturation and is strengthened by somatic mutations that stabilize antigen binding. These findings provide mechanistic insight into autoantibody recognition of neuronal surface proteins and establish a framework for understanding antibody-mediated neurodegeneration in anti-IgLON5 disease. © 2026. The Author(s).
    Type:journal article
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Open Access ,
    Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation
    (2026-08-03)
    Alcaraz-Serna, Ana
    ;
    Chillier, Noémie
    ;
    Trompette, Aurélien
    ;
    Ermellino, Laura
    ;
    Porret, Raphaël
    Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here, we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors-named CAlleR-redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific in vitro activation and suppression and significantly reduced the airway hyperresponsiveness in birch pollen-sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c+ dendritic cells, and were activated in a FcγR-dependent manner by cross-presenting Bet v1 stabilized with noncompetitive anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies. © 2026 Alcaraz-Serna et al.
    Type:research article
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Restricted ,
    Antibody-mediated inhibition of BK virus
    (2026-07-17)
    Vinyals Sales, David
    ;
    Perez, Laurent
    Le virus BK infecte une grande majorité de la population adulte et établit une latence durable en l’absence de symptômes cliniques. Cependant, chez les individus immunodéprimés, une réactivation virale peut survenir et conduire à des manifestations pathologiques. En particulier, chez les patients ayant reçu une greffe rénale, la réactivation virale peut entraîner une néphropathie associée au virus BK, susceptible de conduire à une dysfonction du greffon, voire à sa perte. À l’heure actuelle, il n’existe ni traitement antiviral spécifique ni vaccin contre ce virus. La prise en charge repose donc sur une réduction de l’immunosuppression afin de restaurer partiellement la réponse immunitaire. Toutefois, cette approche ne permet pas toujours de contrôler efficacement la réplication virale ni de prévenir le rejet ou la dysfonction du greffon. Plusieurs études récentes ont montré qu’un taux élevé d’anticorps neutralisants est associé à un meilleur pronostic après transplantation rénale. En effet, ces anticorps jouent un rôle essentiel dans le contrôle du virus. Néanmoins, très peu d’entre eux ont été isolés et évalués dans des essais cliniques à ce jour. Pour ce projet, nous avons d’abord constitué une base de données regroupant des séquences d’anticorps précédemment identifiés, afin de rechercher la présence de motifs communs. Nous avons ensuite sélectionné des donneurs présentant des taux élevés d’anticorps circulants en sang et nous avons identifié, cloné et caractérisé des anticorps neutralisants à partir de leurs lymphocytes B mémoire. La caractérisation fonctionnelle et biochimique de ces anticorps, ainsi que d’autres précédemment identifiés, a montré que la majorité des anticorps neutralisants ciblent un unique site de vulnérabilité à la surface du virus. Ces résultats ouvrent de nouvelles perspectives pour la conception de vaccins et le développement d’immunothérapies.
    Type:thèse de doctorat
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Open Access ,
    Targeting PD-1+ T cells with chimeric antigen receptors to reduce the HIV reservoir
    (2026-04-24)
    Ermellino, Laura
    ;
    Banga, Riddhima
    ;
    Georgakis, Spiros
    ;
    Kadzioch, Nicole P
    ;
    Procopio, Francesco
    The unique ability of chimeric antigen receptor (CAR) T cells to infiltrate tissues is revolutionizing our perspectives for tackling severe, refractory and otherwise untreatable diseases. In HIV, CAR-T cells have been designed to target viral biomarkers, with limited success so far. Here, we investigated the possibility of redirecting CAR-T cells against a cellular biomarker of the HIV reservoir, the programmed cell death protein 1 (PD-1). We designed two second-generation 4-1BB-CARs using the scFv of either a blocking (bPD1-CAR) or a nonblocking (nbPD1-CAR) anti-PD-1 monoclonal antibody. The CAR avidity modulated T cell sensitivity, trogocytosis, and effector functions, independently of the PD-1 signaling domain. Both anti-PD-1 CAR-T cells could persist for 70 days in HIV-infected humanized mice, correlating with viral protection and a disruption of the lymphoid architecture in the white pulp of the spleen. Together, our results open strategic avenues for reducing the HIV reservoir by demonstrating the feasibility of depleting specific T cell subpopulations.
    Type:research article
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Restricted ,
    Enhancement of immune responses by nanoparticle-based vaccination against respiratory syncytial virus
    (2026-03-05)
    Lin, Alison
    ;
    Perez, Laurent
    Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in infants and elderly individuals, populations for whom effective vaccination remains challenging due to age-related immune limitations. This thesis aimed to develop innovative vaccine strategies to enhance humoral immune responses against RSV. To achieve this objective, several vaccine platforms were evaluated: (1) co display of SH and F glycoproteins on the I53-50 nanoparticle to investigate the role of SH in RSV infection and immunity, (2) co-display of F-RSV with a co-immunomodulator that promotes B cell activation, and (3) fusion of F-RSV with a co-immunomodulator. Nanoparticle-displayed F-RSV generated robust neutralizing antibody responses and activated distinct immune transcription programs compared to the trimeric antigen. Co display of SH with F-RSV increased F-specific IgG responses and enhanced neutralizing activity against the RSV-A2 strain, while the addition of APRIL further improved antibody potency. Fusion of F-RSV with IL-21 produced neutralizing activity comparable to nanoparticle-based platforms, increased F-specific IgG titers, and induced antibodies targeting antigenic sites IV and V, which are associated with potent neutralizing responses. In summary, this research demonstrates that integrating multivalent antigen presentation with immunomodulatory approaches or inclusion of the SH protein can enhance humoral immunity against RSV. SH-specific antibodies may facilitate antibody-dependent cellular cytotoxicity and complement the neutralizing activity of F specific antibodies. Furthermore, fusion of F-RSV with IL-21 may promote B cell activation and improve antigen presentation. These findings offer important insights for the development of next-generation RSV vaccines designed for vulnerable populations.
    Type:thèse de doctorat
  • Some of the metrics are blocked by your 
    Item type:Publication,
    BK virus-neutralizing antibodies converge on a shared site of vulnerability on VP1
    (2026)
    Vinyals-Sales, David
    ;
    Foglierini, Mathilde
    ;
    Schelling, Rachel
    ;
    Winiger, Rahel R.
    ;
    Burton, Iszac
    BK virus is a human polyomavirus that infects approximately 80% of adults and establishes lifelong latency. Although primary infection is typically asymptomatic, viral reactivation in kidney transplant recipients can cause BK virus-associated nephropathy, leading to graft dysfunction and rejection. Despite the clinical severity of viral reactivation, antiviral treatment options remain limited. Notably, high serum titers of BK virus-neutralizing antibodies are associated with reduced BK virus DNAemia in kidney transplant recipients, suggesting an important role for humoral immunity in controlling viral replication. Here, we curated a comprehensive database of human antibodies targeting the major capsid protein VP1 by integrating previously reported sequences with newly generated data. Sequence analysis revealed only limited convergence among these antibodies. Nevertheless, functional and biochemical characterization showed that most neutralizing antibodies compete for overlapping epitopes, indicating convergence on a common antigenic site within the receptor-binding cleft of VP1. Together, these findings define an immunodominant site of vulnerability on the BK virus capsid and provide a mechanistic basis for the rational design of vaccines and antibody-based therapies. BK virus (BKV) reactivation is a common complication in kidney transplant recipients, yet no approved antivirals are currently available. The standard of care consists of reducing immunosuppressive therapy, which carries an inherent risk of graft rejection. Antibodies represent promising therapeutic agents for the prevention and treatment of viral infections, particularly when effective vaccines are unavailable. Elucidating the dominant mechanisms of antibody-mediated protection is crucial for guiding the design and optimization of antibody-based therapies. In this study, we identify novel potent neutralizing antibodies against BKV, compare them with previously reported monoclonal antibodies (mAbs), and demonstrate that they compete for binding. Our findings show that most neutralizing mAbs converge on the receptor-binding cleft of VP1, identifying this region as both a major site of vulnerability and a hotspot for immune-driven viral escape, with important implications for therapeutic design.
    Type:journal article
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Chimeric Allergen Receptor regulatory T cells suppress birch pollen allergic airway inflammation.
    (Research Square, 2025)
    Muller, Yannick
    ;
    Alcaraz-Serna, Ana
    ;
    Trompette, Aurelien
    ;
    Porret, Raphaël
    ;
    Lana, Erica
    Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors -named CAlleR- redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific activation and in vitro suppression and significantly reduced the airway hyperresponsiveness in birch pollen- sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c⁺ dendritic cells and were activated in a FcγR-dependent manner by complexing birch allergens with allosteric anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies.
    Type:other
  • Some of the metrics are blocked by your 
    Item type:Publication,
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Open Access ,
    RAIN: machine learning-based identification for HIV-1 bNAbs.
    (2024-06-24)
    Foglierini, M.
    ;
    Nortier, P.
    ;
    Schelling, R.
    ;
    Winiger, R.R.
    ;
    Jacquet, P.
    Broadly neutralizing antibodies (bNAbs) are promising candidates for the treatment and prevention of HIV-1 infections. Despite their critical importance, automatic detection of HIV-1 bNAbs from immune repertoires is still lacking. Here, we develop a straightforward computational method for the Rapid Automatic Identification of bNAbs (RAIN) based on machine learning methods. In contrast to other approaches, which use one-hot encoding amino acid sequences or structural alignment for prediction, RAIN uses a combination of selected sequence-based features for the accurate prediction of HIV-1 bNAbs. We demonstrate the performance of our approach on non-biased, experimentally obtained and sequenced BCR repertoires from HIV-1 immune donors. RAIN processing leads to the successful identification of distinct HIV-1 bNAbs targeting the CD4-binding site of the envelope glycoprotein. In addition, we validate the identified bNAbs using an in vitro neutralization assay and we solve the structure of one of them in complex with the soluble native-like heterotrimeric envelope glycoprotein by single-particle cryo-electron microscopy (cryo-EM). Overall, we propose a method to facilitate and accelerate HIV-1 bNAbs discovery from non-selected immune repertoires.
    Type:journal article
  • Some of the metrics are blocked by your 
    Item type:Publication, Access status: Open Access ,
    Non-uptake of COVID-19 vaccines and reasons for non-uptake among healthcare workers in Uganda: a cross-sectional study.
    (2024-05-25)
    Kyakuwa, N.
    ;
    Abaasa, A.
    ;
    Mpooya, S.
    ;
    Kalutte, H.
    ;
    Atuhairwe, C.
    Vaccines play a crucial role in eradicating and containing disease outbreaks. Therefore, understanding the reasons behind vaccine refusal and associated factors is essential for improving vaccine acceptance rates. Our objective was to examine the determinants of COVID-19 vaccine non-uptake and explore the reasons for non-uptake among healthcare workers (HCWs) in Uganda. Between July and August 2021, we conducted a cross-sectional study among healthcare workers in primary healthcare facilities (private and government) in Entebbe Municipality, Uganda. Participants were recruited using convenience sampling, and consenting individuals received credentials to access an electronic database and complete a structured questionnaire. There were no established HCWs contact registers in the municipality, and the study was conducted during a national lock down, therefore, the HCWs who were on duty at the time of the study were approached. The survey questions were based on the '3Cs' model of vaccine hesitancy and focused on confidence, convenience, and complacency factors. Non-uptake of vaccines was defined as not having received any of the available vaccines in the country. We employed counts, percentages, and simple logit models to summarize the reasons for non-uptake of COVID-19 vaccines and to identify associated factors. The study recruited 360 HCWs, 61.7% of whom were female, with an average age of 31 years (SD = 7.9). Among them, 124 (34.4%) healthcare workers did not receive any COVID-19 vaccine. Non-uptake of COVID-19 vaccines was independently associated with several factors, including age [35 + years adjusted odds ratio (aOR) = 0.30, 95% CI: 0.13-0.66 compared with 18-24 years], facility ownership [government, aOR = 0.22 (0.10-0.49) compared with private not-for-profit], previous testing for coronavirus [yes, aOR = 0.35 (0.19-0.65)], and previous involvement in COVID-19 vaccine activities [yes, aOR = 0.17 (0.10-0.29)]. The primary reasons cited for non-uptake of COVID-19 vaccines were related to a lack of confidence in the vaccines, such as concerns about side effects (79.8%) and the need for more time to understand the vaccines (89.5%), as well as the importance of weighing benefits and risks (84.7%) before being vaccinated. A smaller proportion, approximately 23%, cited reasons related to complacency and lack of convenience in accessing vaccination services. The high proportion of non-uptake of COVID-19 vaccines among this population primarily stems from a lack of confidence and trust in the vaccines, coupled with insufficient time allowed for users to make informed decisions. This underscores the urgent need for ongoing monitoring and trend analysis of vaccine non-uptake to guide the development and implementation of strategies aimed at building and sustaining vaccine confidence. Adequate time should be allowed to explain benefits of vaccination to the population to allay fears that might exist before actual vaccination is rolled out.
    Type:journal article